Introduction {#S1}
============

Serotonin (5-HT) is involved in the etiology of numerous disease states, including depression, anxiety, panic disorders and painful conditions ([@B62]; [@B71]; [@B3]; [@B79]). The 5-HT receptors belong to the G-protein-coupled receptor superfamily (except for the 5-HT3 receptor, which is a ligand-gated ion channel) with at least 14 distinct members ([@B38]), however, the role of 5-HT~1A~ and 5-HT~2*C*~ receptor subtypes in the modulation of emotional and pain responses have been more extensively studied ([@B81]; [@B69]; [@B8]; [@B29]).

Previous findings have been showing that although with antagonistic intracellular mechanisms, 5-HT~1A~ (inhibitory G-coupled protein receptor) and 5-HT~2C~ (stimulatory G-coupled protein receptor) ([@B64]; [@B5]; [@B59]) may interact mutually in the modulation of behavioral and endocrine responses ([@B36]; [@B74]).

Selective serotonin reuptake inhibitors (SSRIs; e.g., fluoxetine) interfere in the modulation of emotions ([@B2]; [@B52]; [@B41]). A body of evidence has been demonstrating that SSRIs provoke the relief of painful symptoms in patients with several pain syndromes, which are frequently associated to emotional disorders, suggesting that these states share biochemical mechanisms ([@B12]; [@B72]; [@B40]). SSRIs also attenuate defensive responses in animal models, provoking anxiolytic and panicolytic effects ([@B79]). In addition, they attenuate pain response in some animal tests ([@B63]) such as the tail-flick and writhing tests for rodents ([@B57]).

The influence of emotional states such as anxiety and fear on pain reaction has been widely investigated in animal models ([@B65]; [@B27]; [@B6]; [@B29]) and the exposure to the elevated plus-maze (EPM), a widely used animal model of anxiety ([@B45]; [@B17]) has been employed to investigate the underlying mechanisms of the anxiety/fear-induced antinociception phenomenon ([@B43]). In this context, previous studies have been showing the role of serotonin at 5-HT~1A~ and 5-HT~2C~ receptors in the modulation of the antinociception induced by the EPM open-arm confinement (OAA) in mice ([@B54]; [@B9]; [@B73]).

Regarding the neurobiological substrate of the anxiety/fear-induced antinociception, several studies have pointed out the crucial role of the amygdaloid complex and the midbrain periaqueductal gray ([@B28]; [@B53]). These areas are markedly involved in the modulation of some types of environmentally induced antinociception, such as the OAA ([@B16]; [@B48]; [@B11]; [@B21]). In this context, many studies have demonstrated that the analgesia induced by stimulation of the PAG is related to areas with a high concentration of serotonergic receptors ([@B46]; [@B20]; [@B14]; [@B83]; [@B47]). In this sense, we have previously reported the role of 5-HT~1A~ and 5-HT~2C~ receptors in reverse and accentuate, respectively, the fear-induced antinociception in mice ([@B7]; [@B29]; [@B73]).

Interestingly, 5-HT~1A~ and 5-HT~2C~ receptor subtypes seem to play antagonistic intracellular mechanisms ([@B64]; [@B5]; [@B59]). For instance, it has been demonstrated that activation of these two serotonin receptors provokes opposite effects on behavioral and endocrine responses ([@B36]; [@B82]; [@B74]). Furthermore, electrophysiology studies have demonstrated that acute and chronic treatment with fluoxetine can differentially modulate the activity of 5HT~1A~ ([@B70]; [@B24]) and 5-HT~2C~ receptors ([@B25]; [@B51]). Moreover, the influence of this interaction on emotional responses was demonstrated by several studies, wherein the anxiolytic and panicolytic responses induced by intra-PAG infusions of 5-HT~1A~ and 5-HT~2~ agonists receptors were accentuated after chronic administration of fluoxetine ([@B22]; [@B80], [@B81]).

Regarding the amygdala, studies have shown that the activation of the 5-HT~1A~ receptors of the basolateral amygdala nucleus (BLA) produces anxiolytic effects in rats exposed to the elevated T-maze (ETM) ([@B69]; [@B77]). On the other hand, Vicente and Zangrossi (2014) also demonstrated that chronic systemic treatment with imipramine and fluoxetine causes desensitization of 5-HT~2C~ receptors in the BLA of rats exposed to the ETM. In this context, [@B73] have recently shown that acute systemic fluoxetine blocked the OAA enhancement induced by intra-amygdala microinjection of MK-212 (a 5-HT~2C~ receptor agonist), suggesting that this SSRI may be acting as a 5-HT~2C~ receptor antagonist. In favor of that interpretation, [@B73] also showed that intra-amygdala combined injection of SB 242084, a selective 5-HT~2C~ receptor antagonist, prior to local injection of MK-212 produced a similar effect on OAA.

Even though these findings above have described specificities concerning fluoxetine mechanisms, it remains unknown the mechanisms by which SSRIs induce rapid neurochemical changes, but take a long time (e.g., weeks) to produce therapeutic efficacy in mood or anxiety disorders. Several studies have shown that this temporal dynamic depends on neuroplastic changes induced by chronic administration of fluoxetine ([@B39]; [@B60]; [@B1]). In this sense, serotonergic receptors would be considered as agents to perform these changes. For this reason, a better understanding of how fluoxetine and 5-HT~1A~ and 5-HT~2C~ receptors interplay may be important to the best usage of this class of drugs on anxiety, depression and pain disorders. Therefore, we hypothesized that chronic treatment with fluoxetine alters the role of 5-HT~1A~ and 5-HT~2C~ receptors located in the amygdaloid complex and PAG in the modulation of OAA in mice.

Here, we evaluated the effects of chronic fluoxetine on serotonin, 5-HIAA levels, the serotonin turnover, 5-HT~1A~, and 5HT~2*C*~ protein levels within the amygdala and the PAG; and the effects of chronic systemic fluoxetine combined with acute intra-amygdala or intra-PAG injections of MK-212 (a 5-HT~2C~ receptor agonist), and the 8-OH-DPAT (a 5-HT~1A~ receptor agonist) on OAA in mice.

Materials and Methods {#S2}
=====================

Animals {#S2.SS1}
-------

Four hundred thirty-three adult male Swiss mice (Federal University of São Carlos, SP, Brazil), weighing 25--30 g, were housed in groups of 10 per cage (cage size: 41 cm × 34 cm × 16 cm). They were maintained under a normal 12:12 h light-dark (LD) cycle (lights on 7:00 a.m.) in a temperature (24 ± 1 °C) controlled environment. Food and drinking water were freely available except during the brief test periods. The experiments were carried out during the light phase of the LD cycle (9:00 am -- 4:00 pm). Different batches of experimentally naïve mice were used for each experiment.

Ethics Statement {#S2.SS2}
----------------

The experiments reported in this study were performed in compliance with the recommendations of the Brazilian Guidelines for Care and Use of Animals for Scientific and Educational Purposes, elaborated by The National Council of Control of Animal Testing (CONCEA). This study was also approved by the Ethics Committee on the Use of Animals of the Federal University of São Carlos (Res. 046/2009; 021/2014). All endeavors were made to reduce animal suffering and to minimize the number of animals used.

Drugs {#S2.SS3}
-----

Fluoxetine hydrochloride, Sigma, (5.0, 10, or 20 mg/Kg, s.c.) were prepared in physiological saline (0.9% NaCl) ([@B66]). 8-OH-DPAT \[(±)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide; Sigma, (10 nmol)\] (5-HT~1A~ receptor agonist); MK-212 \[6-chloro-2-(1-piperazinyl)\] pyrazine hydrochloride, Tocris Cookson Inc. (0.63 nmol) (5-HT~2C~ receptor agonist). Doses used for the intra-amygdala and intra-PAG treatments were based on previous studies ([@B54]; [@B33]; [@B78]; [@B9]; [@B73]). The doses were prepared in saline or vehicle (physiological saline with 2 % of Tween 80) and a final volume of 0.1 μl was injected.

Surgery and Microinjection {#S2.SS4}
--------------------------

For the amygdaloid complex, two stainless-steel guide cannulas (25-gauge × 7 mm; Insight Instruments, Brazil) were implanted under ketamine + xylazine anesthesia (100 mg/kg and 10 mg/kg, i.p.) in a stereotaxic frame (Insight Instruments, Brazil). The guide cannulas were fixed to the skull with dental acrylic. The bregma was considered the reference point, and the following coordinates were used to locate the target site: anterior/posterior, -1.3 mm; medial/lateral, ±3.3 mm; dorsal/ventral, -2.8 mm ([@B56]). Stereotaxic coordinates for the target site in the PAG were 4.1 mm posterior to bregma, +1.3 mm lateral to the midline and 1.2 mm ventral to the skull surface. One guide cannula for the PAG was implanted at an angle of 26° to the vertical and was aimed to terminate 2 mm from the target site. To reduce the incidence of occlusion, a dummy cannula (33-gauge stainless steel wire; Fishtex^®^, Brazil) was inserted into the guide cannula at the time of surgery. During the surgery, animals received ketoprofen (benzeneacetic acid, 5 mg/kg, i.p.) and ceftriaxone (ceftriaxone sodium *hemieptahydrate*, 4 mg/kg, i.p.) ([@B30]; [@B68]). Before behavioral tests, mice were allowed 4--5 days to recover from surgery. The microinjection procedure was performed on the 21st day of treatment with fluoxetine, 30 min after the last injection. Solutions were injected into the amygdala and the PAG by a microinjection unit (33-gauge stainless steel cannula, Insight Instruments, Brazil), that extended 2 mm beyond the tip of the guide cannula. The microinjection unit was connected to a 10 μl Hamilton microsyringe via polyethylene tubing (PE-10) and the rate of flow was controlled by an infusion pump (BI 2000--Insight Instruments, Brazil) programmed to deliver 0.1 μl of each solution over a period of 60 s. The microinjection procedure consisted of gently restraining the mouse, inserting the injection unit, infusing the solution for 60 s and keeping the injection unit in place for 90 s. The movement of a small air bubble in the PE-10 tubing, during and after the microinjection, confirmed the delivery of the solution ([@B54]).

Apparatus and General Procedure {#S2.SS5}
-------------------------------

The basic EPM design was very similar to that originally described by [@B45]. It comprised two open arms (OA: 30 cm × 5 cm × 0.25 cm) and two enclosed arms (EA: 30 cm × 5 cm × 15 cm) that extended in a cross from a common central platform (5 cm × 5 cm), raised to a height 38.5 cm above floor level. Confinement to an OA or EA was achieved by placing an easily removable gate at the proximal end of each arm of the EPM. All testing was conducted under moderate illumination (77 lux; measured on the central platform of the EPM) during the light phase of the LD cycle.

Nociception was assessed by the writhing test as previously described ([@B76]). In the present study, writhes were induced by injecting 0.1 mL/10 g body weight (b.w.) of 0.6% acetic acid i.p, 5 min after the intra-amygdala and intra-PAG drug injection. They were then individually confined to either an OA or an EA of the EPM for 5 min, during which the number of writhes was recorded. Between subjects, the maze was thoroughly cleaned with 20% ethanol and dried with a cloth. All sessions were video recorded with a camera linked to a monitor in an adjacent laboratory. This experimental protocol was repeated in all experiments described below.

Experimental Procedures {#S2.SS6}
-----------------------

### Experiment 1. Effects of Chronic Fluoxetine Treatment on OAA in Mice {#S2.SS6.SSS1}

This protocol aimed to investigate the effects of chronic fluoxetine treatment on antinociception induced by the confinement of mice to the open arms of the EPM, to obtain a dose-response curve of fluoxetine treatment. Sixty-two mice received daily subcutaneous injection of saline or fluoxetine (5, 10 or 20 mg/Kg) for 21 days. Thirty minutes after the last s.c. injection, each animal received an i.p. injection of 0.6% acetic acid (0.1 ml/10 g b.w.), as a nociceptive stimulus, and, 5 min later, was confined either in the enclosed (EA) (*n* = 31) or open arm (OA) (*n* = 31) of the EPM for 5 min to record the number of writhes.

### Experiment 2. Effects of Chronic Fluoxetine Treatment on Serotonin and 5-HIAA Levels and 5-HT Turnover Within the Amygdala and PAG {#S2.SS6.SSS2}

This protocol aimed to investigate whether chronic fluoxetine treatment would increase 5-HIAA levels and 5-HT turnover within the amygdala and PAG. Fifty-three mice received daily subcutaneous injection of saline (*n* = 6) or fluoxetine (5, 10, or 20 mg/Kg; *n* = 6--7) for 21 days. On the last day of treatment and 30 min after the last injection, they were confined either in the enclosed (EA) or open arm (OA) of the EPM and were decapitated in a guillotine and their brains were extracted and stored.

### Experiment 3. Effects of Chronic Fluoxetine Treatment on 5-HT~1A~ and 5-HT~2C~ Protein Levels Within the Amygdala and PAG {#S2.SS6.SSS3}

This protocol aimed to investigate whether chronic fluoxetine treatment changes 5-HT~1A~ and 5-HT~2C~ protein levels within the amygdala and PAG. Twenty-four mice received daily subcutaneous injection of saline (*n* = 8) or fluoxetine (5 or 20 mg/Kg) (*n* = 16) for 21 days, and, 30 min after the last injection, the animals were decapitated in a guillotine and their brains were extracted and stored.

#### Experiment 4. Effects of Combined Treatment With Chronic Systemic Fluoxetine Injection and Acute Bilateral Intra-Amygdala Microinjection of MK-212 or 8-OH-DPAT on OAA {#S2.SS6.SSS4}

This protocol aimed to investigate the effects of the interaction of chronic fluoxetine and the activation of 5-HT~2C~ or 5-HT~1A~ receptors within the amygdala on OAA. One hundred and sixty-four mice received daily subcutaneous injection of saline (*n* = 82) or fluoxetine (5 mg/Kg; *n* = 82) for 21 days. On the 16th day of the chronic treatment, all mice underwent stereotaxic surgery for implantation of guide cannulas in the amygdala. On the 21st day, 30 min after the last s.c. injection of saline or fluoxetine, animals received bilateral intra-amygdala microinjection of vehicle (*n* = 81), MK-212 (0.63 nmol/0.1 μL; *n* = 42) or 8-OH-DPAT (10 nmol/0.1 μL; *n* = 38) and, 5 min later, each mouse received 0.6% acetic acid i.p. injection (0.1 mL/10 g b.w.). Five minutes after acetic acid injection, each mouse was confined either in the OA or in EA of the EPM to record the number of writhes (for details, see [Figure 1A](#F1){ref-type="fig"}).

![**A** and **B** Timeline of the protocol showing the treatment with chronic systemic fluoxetine followed by intra-amygdala or intra-PAG drug injection in mice exposed to the enclosed or open arms of the EPM, **(C)** target sites for microinjection into the amygdala. Schematic representation of microinjection sites into the amygdala. Gray region represent the sites of drug infusion that were on-target in the amygdala **(D)** photomicrograph of a coronal section of a representative subject showing an injection site in the mouse amygdala. **E** The gray region represent the sites of drug infusion that were on-target in the periaqueductal gray. Photomicrography of a coronal section of a representative subject showing an injection site in the mouse PAG **(F).**](fphar-11-00260-g001){#F1}

#### Experiment 5. Effects of Combined Treatment With Chronic Fluoxetine Injection and Intra-PAG Microinjection of MK-212 or 8-OH-DPAT on OAA {#S2.SS6.SSS5}

This protocol aimed to investigate the effects of the interaction of chronic fluoxetine and the activation of 5-HT~2C~ or 5-HT~1A~ receptors within the PAG on OAA. One hundred and thirty-three mice received subcutaneous injection of saline (*n* = 66) or fluoxetine (5 mg/Kg; *n* = 67) for 21 days. On the 21st day, 30 min after the last s.c. injection of saline or fluoxetine, animals received intra-PAG injection of vehicle (*n* = 67), MK-212 (0.63 nmol/0.1 μL; *n* = 34) or 8-OH-DPAT (10 nmol; *n* = 32) and, 5 min later, each mouse received 0.6% acetic acid i.p. injection (0.1 mL/10 g b.w.). Five minutes after acetic acid injection, animals were individually confined either in the EA or OA of the EPM to record the number of writhes (for details, see [Figure 1A](#F1){ref-type="fig"}).

Histology {#S2.SS8}
---------

At the end of testing, the animals of experiments 4, 5 received a 0.1 μl infusion of 1% methylene blue into the amygdala or PAG, exactly as described above for drug microinjection. The animals were then euthanized by anesthetic overdose (300 mg/kg ketamine + 30 mg/kg xylazine, i.p.), their brains removed, and injection sites were verified histologically according to the atlas of [@B56]. Data from animals with injection sites outside the amygdaloid complex and PAG were excluded from the study.

Tissue Processing {#S2.SS9}
-----------------

For experiments 2 and 3, the brains were extracted and frozen in isopentane and stored at - 80 °C until dissection. One-millimeter coronal slices of the brain (rostral face beginning approximately 2.0 mm from Bregma, based on the atlas of [@B56] were cut in a cryostat at -20°C. Tissue punches (using a blunt 15-gauge needle) were obtained from the amygdala and periaqueductal gray (PAG).

High-Performance Liquid Chromatography (HPLC) Assay {#S2.SS10}
---------------------------------------------------

For determination of serotonin (5-HT) levels and its metabolite 5-hydroxyindole acetic acid (5-HIAA), the samples were homogenized in 0.1 M perchloric acid (60 μl), centrifuged at 1300 rpm for 20 min at 4°C; 30 μl of filtrated supernatant was injected into the chromatography system for quantification of the neurotransmitter and its metabolite by electrochemical detection in high-performance liquid chromatography (HPLC). The chromatograph (Waters and Alliance) consists of a Symmetry C18, 5 μm (250 mm × 4.6 mm) and 100 Å pore-diameter particle size, coupled with glassy-carbon electrochemical detector. The potential difference was set at 800 mV versus an Ag/AgCl reference electrode. The mobile phase, in a flow of 0.8 mL/min, with a citric acid constitution (0.05 M), heptane sulfonic acid (1.2 mM), pH 3.2, and after was added methanol (17%) for adjusting for pH.

The calibration curve was constructed with standard internal solutions of 1, 2.5, 5, 10, 25, 50, 100, 200, 400, and 600 ng/mL which were injected into the chromatograph in triplicate. The limit of detection and quantitation, as already standardized in this apparatus were: 1.0 to 3.5 for serotonin and 1.3 and 4.26 ng/mL for 5-HIAA. Finally, the levels of substances were corrected according to the mass from the dissected samples and were expressed as ng of substance per milligram of tissue. As an activation parameter, we used the serotonin turnover rate. The turnover was calculated by the ratio between metabolite and its respective neurotransmitter ([@B19]).

Western Blot {#S2.SS11}
------------

After the area dissection, samples were sonicated in 1% sodium dodecylsulfate (SDS), and the protein concentration was determined by Bio-Rad DC protein assay (Bio-Rad Laboratories Inc., Hercules, CA, United States). Twenty micrograms of protein of each sample were boiled for 5 min in a loading buffer containing 5% of b-Mercaptoethanol and 0.002% of Bromophenol Blue and subjected to electrophoresis in 9% SDS-polyacrylamide minigels for 50 or 60 min at 200 V using the BioRad Mini-PROTEAN tetra cell with Bio-Rad Powerpac basic supply (Bio-Rad Laboratories Inc.). Proteins were electrophoretically transferred to low-fluorescence polyvinylidene fluoride membranes (LFPVDF) using the *Trans-*Blot Turbo system (Bio-Rad Laboratories Inc.). Membranes were washed in TBS-Tween 20 (TBS-T) buffer, pH 7.4 and blocked with 5% non-fat dry milk TBS-T, pH 7.4, for 1 h at room temperature. Membranes were then incubated with antibodies for both 5HT~1A~ (1:1000 Sigma-Aldrich, Cat. n°SAB4501469; polyclonal anti-rabbit, synthesized peptide derived from human, mol. wt 45 kDa) or anti-5-HT~2C~ (1:1000 Abcam, Cat. n°AB137529; polyclonal anti-rabbit, corresponding to a region within amino acids 387--436 of Human 5HT~2C~ Receptor, mol. wt 50 kDa) overnight at 4°C. Next, membranes were washed extensively with TBS-T solution, incubated for 60 min with HRP-conjugated anti-rabbit IgG (1:2000; Amersham Pharmacia Biotech^®^), and washed extensively again in TBS-T. Protein bands were visualized on a Kodak Biomax Light film with enhanced chemiluminescence (ECL plus, Amersham Pharmacia Biotech^®^). Equal protein loading was confirmed by stripping the blots and reprobing them with a monoclonal β-actin antibody (1:500 Santa Cruz Biotechnology^®^), followed by incubation with secondary antibody and visualization as described above. The films were scanned in transparency mode and the volume of the bands was quantified using Image-Master^®^ software (Amersham Pharmacia Biotech^®^) with the subtraction of background. As determined by preliminary experiments, all assays were conducted under conditions in which densitometric signal intensity was linear with protein concentration.

Statistical Analysis {#S2.SS12}
--------------------

The data of experiments 1 and 2 were analyzed by two-way analysis of variance (ANOVA) (treatment × type of confinement) and experiment 3 was analyzed by one-way ANOVA (treatment factor). Data of experiments 4 and 5 were analyzed by three-way ANOVA (systemic treatment × intra-PAG or intra-amygdala treatment × type of confinement). In cases of significant interactions, single effects of the factors were analyzed by one-way ANOVAs followed by the Duncan test. A *p*-value of 0.05 or less was required for significance.

Results {#S3}
=======

For experiments 4 and 5, only mice with microinjection sites located bilaterally in the amygdala and unilaterally in the PAG were included in the study. [Figures 1C](#F1){ref-type="fig"}, [1E](#F2){ref-type="fig"} show a schematic representation of histological results according to the Mouse Brain Atlas (2001). Gray areas represent on-target of infusion within the amygdala and PAG. [Figures 1D,F](#F2){ref-type="fig"} show photomicrographs of a midbrain coronal section of a representative subjects showing an injection site within the amygdala and PAG, the arrows represents the injection sites.

![Effect of chronic treatment of fluoxetine (5, 10, and 20 mg/kg, s.c.) on nociceptive response of EA- and OA-confined mice (*n* = 7--9). Data are presented as mean + SEM. ^\#^*p* \< 0.05 vs. EA-confined group. \**p* \< 0.05 vs. respective control group.](fphar-11-00260-g002){#F2}

Experiment 1: Fluoxetine Enhanced OAA {#S3.SS1}
-------------------------------------

Two-way ANOVA revealed significant effects for the type of confinement factor \[*F*(1,54) = 83.10, *p* \< 0.05\], for the treatment factor (*F*(3,54) = 9.57, *p* \< 0.05\], and no interaction between factors type of confinement and treatment factor \[*F*(3,54) = 1.16, *p* = 0.33\]. Duncan's *post hoc* test indicated that the number of writhes was significantly higher in EA-confined animals than in the OA group. Furthermore, animals that received fluoxetine (20 mg/kg) and were confined in the EA or OA displayed a lower number of writhes compared to their respective control groups ([Figure 2](#F2){ref-type="fig"}).

Experiment 2: Effects of Chronic Fluoxetine Treatment on Serotonin, 5-HIAA Levels and Turnover Within the Amygdala and PAG in Mice {#S3.SS2}
----------------------------------------------------------------------------------------------------------------------------------

### Amygdala {#S3.SS2.SSS1}

5-HT levels: two-way ANOVA revealed significant effects for confinement versus treatment interaction \[*F*(3,44) = 3.55, *p* \< 0.05\], but not for treatment factor \[*F*(3,44) = 2.06, *p* = 0.17\] and type of confinement factor \[*F*(1,44) = 3.90, *p* = 0.08\] ([Figure 3A](#F3){ref-type="fig"}).

![Effects of chronic treatment with fluoxetine (5, 10, and 20 mg/kg, s.c.) on the levels of 5-HT **(A)**, 5-HIAA (**B),** and serotonin turnover **(C)** within the amygdala. Levels of serotonin **(D)**, 5-HIAA (**E),** and serotonin turnover **(F)** in nanograms *per* tissue within the PAG in mice confined in the open or enclosed arms of the EPM (*n* = 5--7). Data are represented as mean + SEM. ^\#^*p* \< 0.05 vs. EA-confined group, ^∗^*p* \< 0.05 vs. respective control group.](fphar-11-00260-g003){#F3}

5-HIAA levels: two-way ANOVA revealed no significant effects for type of confinement factor \[*F*(1,44) = 1.60, *p* = 0.21\]; treatment \[*F*(3,44) = 0.55, *p* = 0.64\] for confinement versus treatment interaction \[*F*(3,44) = 0.20, *p* = 0.89\] ([Figure 3B](#F3){ref-type="fig"}).

5-HT turnover: two-way ANOVA showed significant effects for treatment factor \[*F*(4,44) = 3.22, *P* \< 0.05\], but not for type of confinement factor \[*F*(1,44) = 0.54, *p* = 0.89\] and treatment versus type of confinement interaction \[*F*(3,44) = 1.14, *p* = 0.34\] ([Figure 3C](#F3){ref-type="fig"}).

*Post hoc* analyses confirmed that the serotonin levels were significantly higher in mice that received 20 mg/kg of fluoxetine and were confined in OA than in EA-confined animals ([Figure 3A](#F3){ref-type="fig"}). Duncan's *post hoc* test also revealed a significantly lower serotonin turnover in mice that received 20 mg/kg of fluoxetine ([Figure 3C](#F3){ref-type="fig"}).

### PAG {#S3.SS2.SSS2}

5-HT levels: two-way ANOVA revealed significant effects for the type of confinement factor \[*F*(1,48) = 5.55, *p* \< 0.05) and did not for treatment \[*F*(3,45) = 0.30, *p* = 0.82\] and interaction \[*F*(3,45) = 0.41, *p* = 0.74\] ([Figure 3D](#F3){ref-type="fig"}).

5-HIAA levels: two-way ANOVA revealed effects for the type of confinement factor \[*F*(1,45) = 6.84, *p* \< 0.05\] and did not for treatment \[*F*(3,46) = 0.57, *p* = 0.63\] and interaction \[*F*(3,46) = 2.45, *p* = 0.07\] ([Figure 3E](#F3){ref-type="fig"}).

Duncan's *post hoc* test confirmed that the 5-HIAA levels were significantly lower in the mice that received 10 mg/kg de fluoxetine and were confined in OA than EA-confined animals ([Figure 3E](#F3){ref-type="fig"}).

5-HT turnover: two-way ANOVA revealed no significant effects for type of confinement factor \[*F*(1,44) = 0.09, *p* = 0.75\]; treatment \[*F*(3,44) = 1.46, *p* = 0.23\] for confinement versus treatment interaction \[*F*(3,44) = 0.86, *p* = 0.46\].

Experiment 3: Effects of Chronic Systemic Fluoxetine on 5-HT~1A~ and 5-HT~2C~ Protein Levels in the Amygdala and PAG {#S3.SS3}
--------------------------------------------------------------------------------------------------------------------

### Amygdala {#S3.SS3.SSS1}

5-HT~1A~ receptor: One-way ANOVA revealed no significant differences \[F(2,24) = 0.30; *p* = 0.74\] ([Figure 4A](#F4){ref-type="fig"}).

![Effects of chronic treatment (21 days) with fluoxetine (5 and 20 mg/kg) on the 5-HT~1A~ and 5-HT~2C~ protein levels receptors in the amygdala (**A** and **B**, respectively) and PAG (**C** and **D**, respectively). ^∗^*p* \< 0.05 vs. respective control group.](fphar-11-00260-g004){#F4}

5-HT~2C~ receptor: One-way ANOVA revealed a significant difference \[F(2,23) = 77.18; *p* \< 0.05\] and *post hoc* test confirmed that animals that received the 20 mg/kg of fluoxetine showed an increase in 5-HT~2*C*~ receptor protein levels compared to the control group ([Figure 4B](#F4){ref-type="fig"}).

PAG {#S3.SS4}
---

5-HT~1A~ receptor: one-way ANOVA revealed significant differences \[F (2,18) = 12.49, *p* \< 0.05\] and *post hoc* test confirmed that both doses of fluoxetine increased 5-HT~1A~ receptor protein levels compared to the control group ([Figure 4C](#F4){ref-type="fig"}).

5-HT~2C~ receptor: one-way ANOVA revealed significant difference \[*F*(2,23) = 16.40, *p* \< 0.05\] and *post hoc* analyses confirmed that both doses of fluoxetine increased 5-HT~2C~ receptors protein levels compared to the control group ([Figure 4D](#F4){ref-type="fig"}).

Experiment 4: Chronic Systemic Fluoxetine Impairs the Effects of Intra-Amygdala Microinjection MK-212 or 8-OH-DPAT on OAA {#S3.SS5}
-------------------------------------------------------------------------------------------------------------------------

### Chronic Fluoxetine × Intra-Amygdala MK-212 {#S3.SS5.SSS1}

Three-way ANOVA revealed statistically significant main effects for type of confinement factor \[*F*(1, 69) = 57.90, *p* \< 0.05\] and for confinement × chronic systemic treatment factor × intra-amygdala treatment interactions \[*F(*2,69) = 5.62, *p* \< 0.05\], but not for chronic treatment \[*F*(1,69) = 0.19, *p* = 0.65\], intra-amygdala treatment \[*F*(1,69) = 2.38, *p* = 0.13\], interaction between confinement and chronic treatment \[*F*(1,69) = 2.67, *p* = 0.10\], confinement and intra-amygdala treatment \[*F*(1,69) = 0.39 *p* = 0.53\], and between treatments \[*F*(1,69) = 0.64, *p* = 0.42\].

Again, the *post hoc* test confirmed that OA-confined animals displayed a lower number of writhes than in the EA-confined group. In addition, intra-amygdala injection of MK-212 increased OAA, but only in animals that received saline systemically. In other words, chronic fluoxetine prevented the enhancement of OAA-induced by intra-amygdala injection of MK-212 ([Figure 5A](#F5){ref-type="fig"}).

![Effects of the combined injections of chronic systemic fluoxetine (5.0 mg/kg) followed by bilateral intra-amygdala microinjections of 8-OH-DPAT (10 nmol/0.1 μL) **(A)** and MK-212 (0.63 nmol/0.1 μL) **(B)** on OAA in mice. All data are presented as mean + SEM (*n* = 7--12). ^\#^*p* \< 0.05 compared to EA-confined group. ^∗^*p* \< 0.05 compared to the respective vehicle group. ^1^*p* \< 0.05 compared to the saline + 8-OH-DPAT group or saline + MK-212 group. Three-way ANOVA followed by Duncan's *post hoc* test.](fphar-11-00260-g005){#F5}

### Chronic Fluoxetine × Intra-Amygdala 8-OH-DPAT {#S3.SS5.SSS2}

Three-way ANOVA revealed significant effects for the type of confinement factor \[*F*(1,72) = 30.97, *p* \< 0.05\], systemic treatment factor \[*F*(1, 72) = 4.50, *p* \< 0.05\], and for intra-amygdala treatment factor \[*F*(1, 72) = 4.96, *P* \< 0.05\].

Although, the statistical analysis did not reveal significance for interaction between confinement and chronic treatment \[*F*(1,72) = 0.008, *p* = 0.97\], confinement and intra-amygdala treatment \[*F*(1,72) = 0.20 *p* = 0.65\], treatments systemic and intra-amygdala \[*F*(1,72) = 2.50, *p* = 0.11\], and for interaction local of confinement, treatment systemic and intra-amygdala \[*F(*1,72) = 0.74, *p* = 0.39\].

Duncan's *post hoc* test confirmed the lower number of writhes in the OA-confined group than in the EA-confined group. Also, for OA-confined animals, the saline + 8-OH-DPAT group increased the number of writhes compared with saline + vehicle-treated animals. Importantly, fluoxetine did not produce any effect *per se* on nociceptive response either in OA- or EA-confined animals. Overall, these data indicate that the attenuation of the OAA, observed in mice treated with saline + 8-OH-DPAT, was prevented by chronic fluoxetine treatment ([Figure 5B](#F5){ref-type="fig"}).

Experiment 5: Chronic Fluoxetine Treatment Alters the Effects of Intra-PAG Microinjection of MK-212 or 8-OH-DPAT and on OAA in Mice {#S3.SS6}
-----------------------------------------------------------------------------------------------------------------------------------

### Chronic Fluoxetine × Intra-PAG MK-212 {#S3.SS6.SSS1}

Three-way ANOVA revealed significant effects for type of confinement factor \[*F*(1,85) = 100.21, *p* \< 0.05\], intra-PAG treatment \[*F*(2,85) = 3.13, *p* \< 0.05\] and systemic × intra-PAG × type of confinement interaction \[*F*(2,85) = 3.72, *p* \< 0.05\], but not for systemic treatment \[*F*(1,85) = 0.65 *p* = 0.41\], confinement and chronic treatment \[*F*(1,85) = 1.27, *p* = 0.26\], confinement and intra-PAG treatment \[*F*(2,85) = 2.52, *p* = 0.08\], treatments systemic and intra-PAG \[*F*(1,85) = 0.30, *p* = 0.73\].

*Post hoc* analyses confirmed that the number of writhes was significantly higher in EA-confined animals than in the OA group and that OA-confined animals treated with MK-212 (saline + MK-212) exhibited a lower number of abdominal contortions than the control group (saline + vehicle). However, the enhancement of OAA induced by intra-PAG MK-212 was prevented by chronic fluoxetine. Importantly, fluoxetine *per se* (fluoxetine + vehicle) did not significantly change nociceptive response in EA- or OA-confined animals ([Figure 6A](#F6){ref-type="fig"}).

![Effects of combined injections of systemic fluoxetine (5 mg/kg) and intra-PAG 8-OH-DPAT (10 nmol/0.1 μl) **(A)** or MK-212 (0.63 nmol/0.1 μL) **(B)** on OAA in mice (*n* = 7--10). Data are presented as mean + SEM. ^\#^*p* \< 0.05 vs. EA-confined group. ^∗^*p* \< 0.05 vs. respective control group. ^1^*p* \< 0.05 vs. saline + MK-212 group or saline + 8-OH-DPAT.](fphar-11-00260-g006){#F6}

### Chronic Fluoxetine × Intra-PAG 8-OH-DPAT {#S3.SS6.SSS2}

Three-way ANOVA revealed significant effects for type of confinement factor \[*F*(1,64) = 91.53, *p* \< 0.05\], systemic treatment factor \[*F*(1,64) = 6.82, *p* \< 0.05\], intra-PAG treatment factor \[*F*(2,64) = 12.25, *p* \< 0.05\], confinement × intra-PAG interaction \[*F*(1,64) = 5.43, *p* \< 0.05\] and confinement × intra-PAG interaction × systemic treatment interactions \[*F*(1,64) = 4.52, *p* \< 0.05\], but not for interaction type of confinement and systemic treatment \[*F*(1,64) = 0.72, *p* = 0.39\] and between treatments \[*F*(1,64) = 1.10, *p* = 0.29\].

Apart from confirming the occurrence of the OAA for almost all groups, *post hoc* analyses also revealed that chronic fluoxetine combined with intra-PAG injection of 8-OH-DPAT prevented this type of fear-induced antinociception, i.e., OA-confined animals that received fluoxetine + 8-OH-DPAT did not exhibit antinociceptive response ([Figure 6B](#F6){ref-type="fig"}).

Discussion {#S4}
==========

This work sought to confirm that chronic treatment with fluoxetine impairs the effects produced by the activation of 5-HT~1A~ and 5-HT~2C~ receptors located in the amygdala and PAG on OAA.

Chronic fluoxetine treatment at the dose of 20 mg/kg reduced the number of writhes in both EA- and OA-confined animals, indicating an antinociceptive effect of this SSRI (Fig. 2). At this highest dose, fluoxetine also enhanced 5-HT levels and decreased the turnover of this monoamine in the amygdala ([Figures 3A,C](#F3){ref-type="fig"}), suggesting that this SSRI may be increasing 5-HT releasing without enhancing its synthesis. Interestingly, statistics confirmed between factor interactions for 5-HT levels, i.e. such effects on 5-HT neurotransmission occurred only in OA-confined mice, suggesting that the enhancement of the OAA produced by fluoxetine may be mediated by 5-HT action in the amygdala, in spite of the absence of statistical significance interaction between factors. Given that chronic treatment with 20 mg/kg of fluoxetine also increased 5-HT~2C~ receptor protein in the amygdala, it seems reasonable to suggest that 5-HT may be facilitating OAA through activation of 5-HT~2C~ receptors in this forebrain area. Regarding the 5-HT neurotransmission in the PAG, chronic fluoxetine did not produce any robust effect on 5-HT and 5-HIAA levels and in its turnover ([Figures 3D--F](#F3){ref-type="fig"}).

Although no study has directly explored the effect of fluoxetine in *post mortem* tissue, *in-vivo* microdialysis has shown that acute systemic injection of the SSRI citalopram enhances 5-HT levels in the amygdala ([@B13]; [@B32]). A similar effect on serotonin levels was observed when the SSRI fluvoxamine was injected into the amygdala ([@B75]). Additionally, [@B81] demonstrated that chronic fluoxetine (10 mg/kg) increased 5-HT extracellular levels in the PAG of rats. Thus, it is possible that chronic fluoxetine increases serotonin levels in the amygdala of mice (present results) and also in the midbrain periaqueductal gray of rats ([@B81]).

Despite chronic fluoxetine at the dose of 5.0 mg/kg did not change nociceptive response in EA- and OA-confined animals, as well as unchanged 5-HT neurotransmission either in the amygdala or in PAG, this lowest dose of fluoxetine strongly increased 5-HT~1A~ and 5-HT~2C~ receptor densities in the PAG. These apparently contrasting results on behavioral and neurochemical responses produced by 5.0 mg/kg chronic fluoxetine suggest that the changes in the 5-HT neurotransmission are dependent on the dose of this SSRI. The mechanism underlying the increases in both 5-HT~1A~ and 5-HT~2C~ receptor densities in the PAG produced by 5.0 mg/kg chronic fluoxetine remains to be determined. However, although fluoxetine is known as an SSRI ([@B10]; [@B31]), subsequent findings revealed that it would also be able to block 5-HT~2C~ receptor ([@B15]; [@B18]; [@B26]; [@B67]), and up-regulate this 5-HT~2C~ receptor subtype in the choroid plexus ([@B42]; [@B55]) and in the PAG of rats. Thus, it is likely that the prolonged blockade of 5-HT~2C~ receptors because of chronic fluoxetine treatment has up-regulated this 5-HT receptor subtype in the amygdala and PAG (Fig. 4B-D).

Corroborating the possibility of antagonistic property induced by fluoxetine at 5-HT~2*C*~ receptors, [@B73] have recently demonstrated that acute systemic administration of fluoxetine or intra-amygdala injection of SB 242084 (a selective 5-HT~2C~ receptor antagonist) prevented the enhancement of OAA provoked by intra-amygdala injection of MK-212. In this context, the results of experiment 4 seem to confirm the potential role of fluoxetine as a 5-HT~2C~ antagonist receptor. Given that the activation of the 5-HT~2C~ receptors intensified OAA without changing nociceptive response in EA-confined animals, we suggest that this 5-HT receptor subtype selectively modulates pain inhibition induced by aversive situations (e.g., the OA exposure). Moreover, chronic fluoxetine prevented OAA enhancement induced by intra-amygdala MK-212. Together, these results suggest that fluoxetine could plays an antagonist role at 5-HT~2C~ receptors, impairing the facilitatory effects of MK-212 on OAA.

We do not have a clear explanation of why the lowest dose of fluoxetine (5.0 mg/kg) given chronically also increased 5-HT~1A~ receptor protein in the PAG, but not in the amygdala. However, previous studies have shown that 5-HT~1A~ and 5-HT~2C~ receptor subtypes seem to play antagonistic intracellular roles ([@B64]; [@B5]; [@B59]). For instance, it has been demonstrated that activation of these two serotonin receptors provokes opposite effects on behavioral and endocrine responses ([@B36]; [@B82]; [@B74]). If so, the increased in 5-HT~2C~ receptor density following chronic fluoxetine could indirectly have increased 5-HT~1A~ receptor expression in the PAG. Such a neuroplastic mechanism would counteract an over activation of 5-HT~2C~ receptors. Although attractive this hypothesis needs further investigation.

Despite fluoxetine has not changed 5-HT1A receptor density in the amygdala, it prevented the effects of local injection of 8-OH-DPAT on OAA. Although three-way ANOVA did not reveal any statistically significant interaction effects among the factors, *post hoc* analyses pointed out that intra-amygdala injection of 8-OH-DPAT selectively attenuated OAA, i.e. it did not change nociceptive response in EA-confined animals. We expected that the blockade of 5-HT~2C~ receptors in mice chronically treated with fluoxetine would enhance (*instead of* impairing) the effects of 8-OH-DPAT in the modulation of OAA. However, fluoxetine prevented the attenuation of OAA triggered by activation of 5-HT~1A~ receptors in the amygdala. 5-HT~1A~ receptors are highly expressed in the amygdaloid complex ([@B35]; [@B4]) and their activation has been shown to produce anxiolytic-like behavior in several animal models of anxiety ([@B69]). If so, we suggest that the enhancement in the number of writhes in OA occurred due to the attenuation in anxiety caused by 5-HT~1A~ receptor activation.

Similarly to the results obtained in the amygdala, experiment 5 showed that intra-PAG injection of MK-212 also intensified OAA, an effect that corroborates previous studies (e.g., [@B7]; [@B9]). Again, activation of 5-HT~2C~ receptors in the PAG selectively enhanced OAA without changing nociceptive response in EA-confined animals. Once more, chronic fluoxetine prevented the effects of MK-212 on OAA, i.e., OA-confined mice that received this SSRI exhibited a similar number of writhes compared to those systemically treated with saline. Importantly, 5.0 mg/kg fluoxetine *per se* did not provoke any effect on nociception in EA-confined animals, indicating its selective effect on blocking MK-212 effects on OAA.

Intra-PAG injection of 8-OH-DPAT failed to change nociceptive response in EA- and OA-confined animals. This result corroborates a previous study showing that 5.6 or 10 nmol of 8-OH-DPAT injected into the PAG failed to alter nociception in mice exposed to the EPM ([@B7]). Interestingly, when given with chronic fluoxetine, intra-PAG injection of 8-OH-DPAT abolished OAA. This result suggests that the blockade of 5-HT~2C~ receptor exerted by fluoxetine facilitates the anti-antinociceptive effect produced by 5-HT~1A~ receptor activation in the PAG in OA-confined mice. It is noteworthy that fluoxetine combined with intra-PAG 8-OH-DPAT did not produce any intrinsic effect on the nociception of EA-confined animals.

This assumption corroborates [@B74] who showed that activation of 5-HT~2~ receptor selectively attenuated 5-HT~1A~ receptor activity in neurons of the anterior cingulate cortex of rats. Therefore, it is possible to presume that blockade of 5HT~2C~ receptor produced by fluoxetine may have cooperated with 8-OH-DPAT binding at the 5HT~1A~ receptor, facilitating its effects on OAA. Together, the results of exp. 5 suggests that 5-HT modulates differentially OAA at 5-HT~1A~ and 5-HT~2C~ receptors located in the midbrain PAG. While this indolamine facilitates OAA at 5-HT~2C~ receptors, it plays an opposite effect at 5-HT~1A~ receptors on this type of fear-induced antinociception. However, present results also emphasize that the activation of the PAG 5-HT~1A~ receptors *per se* is not enough to impair OAA. To that end, it is necessary to antagonize local 5-HT~2C~ receptors to abolish it, as shown in OA-confined animals that received chronic fluoxetine treatment.

Previous studies have described that the dimerization between serotonergic receptor subtypes could explain the interplay among them. In this sense, the heterodimerization most known is 5-HT~1A~-5-HT~7~ receptors for while the heterodimers described for 5-HT~2C~ receptors involves the ER (estrogen receptor) ([@B37]). Regarding these ability for dimerization of these serotonin receptors it is possible that the interaction observed in the present study could be result of the heterodimerization 5-HT~1A~-5-HT~2C~ receptors. However, this hypothesis needs to be confirmed in future molecular experiments.

Considering that the classical mechanism described with the administration of SSRI's is to increase the extracellular levels of this neurotransmitter ([@B50]) and that 5-HT~1A~ auto-receptors are directly related to the control of the serotonin release levels, resulting in the decrease of the serotonin release, these autoreceptors (5-HT~1A~) are essential to act as a compensatory mechanism, decreasing serotonin release ([@B23]). If so, we suggest that the up-regulation of 5-HT~1A~ receptor within the PAG and amygdala occurs in post synaptic neurons, since previous studies have demonstrated that chronic treatment with SSRIs provoke a 5-HT~1A~ autoreceptors desensitization and internalization ([@B44]; [@B34]).

Considering all the above-mentioned evidence concerning the mechanisms exerted by chronic fluoxetine administration, it is conceivable to note the distinct roles of 5-HT~1A~ and 5-HT~2C~ receptors in the modulation of OAA in the amygdaloid complex and PAG. We suggest that this dissimilarity may be due to the differences in the expression of this subtype of receptors in these areas ([@B61]; [@B49]; [@B58]). Altogether, the present findings provide evidence that fluoxetine promotes functional and quantitative changes in the 5-HT~1A~ and 5-HT~2C~ receptors located in the amygdaloid complex and PAG. If so, these neuroplasticities might be related to the necessary temporal dynamic for the therapeutic efficacy of SSRIs.
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